You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 53 No. 11, November 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Change in Cognitive Function in Idiopathic Parkinson Disease

Kathryn A. Bayles, PhD; Cheryl K. Tomoeda, MS, CCC-SLP; Jody A. Wood; Erwin B. Montgomery, Jr, MD; Robyn F. Cruz, PhD; Tamiko Azuma, PhD; Anna McGeagh, MEd

Arch Neurol. 1996;53(11):1140-1146.


Abstract

Objective
To study the effects of Parkinson disease (PD) on cognitive function by determining the frequency and amount of change in Mini-Mental State Examination (MMSE) performance.

Design
During a 4-year period, 77 patients with idiopathic PD and 43 normal elders were administered a neuropsychological test battery twice at 2 years apart.

Results
A 4-point score difference on the MMSE was the amount that was statistically calculated to be a significant difference at the.05 probability level. Using this metric, 17 (22%) patients with PD had a change in their MMSE performance during a 2-year period. Fifteen individuals performed poorer, and 2 individuals improved. Using the same metric, no normal subjects changed in their MMSE performance. The groups of patients with PD who had a change and did not have a change in their MMSE performance were not characterized by significant differences in their years of education, duration of illness, age at onset, age at test time 1, estimated premorbid intelligence, Hamilton Psychiatric Rating Scale for Depression score at test time 1, or Unified Parkinson's Disease Rating Scale score. The singular difference was the higher frequency of change that was found in subjects who were taking dopamine agonists at the second test time.

Conclusion
A change in cognitive function in patients with PD, as measured by a change of 4 points or more in their MMSE performance, was observed in only 22% of a sample of 77 patients with idiopathic PD during a 2-year period.



Author Affiliations

From the Departments of Speech and Hearing Sciences (Dr Bayles) and Neurology (Dr Montgomery) and the National Center for Neurogenic Communication Disorders (Drs Bayles, Cruz, and Azuma and Mss Tomoeda, Wood, and McGeagh), University of Arizona Main Campus and College of Medicine, Tucson.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Rate of Cognitive Decline in Parkinson Disease
Aarsland et al.
Arch Neurol 2004;61:1906-1911.
ABSTRACT | FULL TEXT  

Predictors of cognitive impairment in advanced Parkinson's disease
Vingerhoets et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:793-796.
ABSTRACT | FULL TEXT  

Are Late-Onset Schizophrenia Spectrum Disorders Neurodegenerative Conditions? Annual Rates of Change on Two Dementia Measures
Palmer et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:45-52.
ABSTRACT | FULL TEXT  

Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy
Soliveri et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:313-318.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.